Eli Lilly announced significant advancements in its next-generation obesity treatment, retatrutide, showcasing promising results from its latest clinical trial. This groundbreaking drug has reportedly led to the highest weight loss observed to date in a late-stage trial while also providing relief from knee arthritis pain. The findings come as part of Eli Lilly’s strategic efforts to strengthen its position in the competitive obesity and diabetes medication markets.
In the trial, participants with obesity and knee osteoarthritis experienced an average weight reduction of 23.7% over 68 weeks when including all participants, illustrating the drug’s efficacy even among those who discontinued its use. For patients who remained on the treatment, the average weight loss was even higher at 28.7%. Interestingly, some individuals lost so much weight that they opted out of the study, underscoring the transformative impact of retatrutide.
News of these results buoyed Eli Lilly’s stock, which saw a more than 2% increase in premarket trading. This trial marks the initial late-stage data release for retatrutide, which distinguishes itself from existing weight-loss injections by employing a novel mechanism of action. Eli Lilly aims to make retatrutide a cornerstone of its obesity drug portfolio, complementing its other offerings, including the established injection Zepbound and a forthcoming oral medication.
Despite the promising data, the timeline for retatrutide’s market release remains uncertain. The drug is critical to Eli Lilly’s strategy to maintain a significant market share against its primary competitor, Novo Nordisk, in a sector projected to be worth approximately $100 billion by the 2030s.
In addition to weight loss, retatrutide also successfully met its secondary trial objective of alleviating pain associated with knee osteoarthritis, decreasing discomfort by an average of 62.6% across all participants. Notably, over 12.5% of those treated with the drug reported being completely pain-free by the trial’s conclusion. This dual benefit positions retatrutide as a potentially vital option for patients grappling with obesity and related complications such as knee arthritis.
Analysts had set expectations for the trial, with one suggesting a weight loss range of 20% to 23% while anticipating at least a 50% reduction in knee pain. Kenneth Custer, president of Lilly Cardiometabolic Health, emphasized in a statement that retatrutide could fill a significant need among patients requiring substantial weight loss.
However, the trial also revealed challenges, as approximately 18% of participants on the highest dose discontinued treatment due to side effects, significantly higher than the 4% seen in the placebo group. The researchers identified that dropout rates were closely linked to initial body mass index (BMI) and included instances where patients perceived themselves to be losing too much weight. Among the side effects reported, nausea affected about 43% of participants, while diarrhea and vomiting were reported by 33% and 20.9%, respectively.
The study, named TRIUMPH-4, was not exclusively concentrated on weight loss, indicating that further focused trials could yield different outcomes. Eli Lilly plans to disclose results from an additional seven phase three trials on retatrutide by the close of 2026.
Retatrutide operates uniquely by mimicking three hunger-regulating hormones—GLP-1, GIP, and glucagon—rather than one or two, as seen in existing treatments. This multifaceted approach appears to enhance appetite control and satisfaction with food compared to competing drugs. For context, Eli Lilly’s tirzepatide, the active component of Zepbound, mimics GLP-1 and GIP, achieving an average weight reduction of up to 22.5% in prior late-stage studies.
As Eli Lilly advances in this sector, Novo Nordisk continues to explore competitive options. Recently, Novo Nordisk announced a significant investment in a new experimental drug from China, which employs a similar three-hormone approach. However, this treatment remains in the early stages of development, suggesting it may be years before it becomes available to patients.
